Teva Pharmaceutical Industries (NYSE:TEVA) Stock: Insider Richard Daniell Sells 20,003 Shares

Key Points

• Insider Richard Daniell sold 20,003 Teva shares at an average $42.80, worth about $856,000, reducing his direct stake by 26.4% to 55,755 shares. He had also sold 25,000 shares earlier that week.
• Teva beat quarterly earnings expectations, reporting $0.86 per share versus analysts’ $0.72 estimate and revenue of $4.39 billion versus $4.23 billion expected; revenue nevertheless fell 1.9% year over year.
• Analyst sentiment was generally positive: 13 analysts rated the stock Buy, with an average target of $48.15. Teva also set a goal of $6 billion–$7 billion in innovative-medicines revenue by 2030.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Get Free Report) EVP Richard Daniell sold 20,003 shares of the firm's stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $42.80, for a total value of $856,128.40. Following the completion of the transaction, the executive vice president directly owned 55,755 shares in the company, valued at $2,386,314. This trade represents a 26.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Richard Daniell also recently made the following trade(s):

• On Monday, November 9th, Richard Daniell sold 25,000 shares of Teva Pharmaceutical Industries stock. The shares were sold at an average price of $42.91, for a total value of $1,072,750.00.

Teva Pharmaceutical Industries Stock Up 0.7%

Shares of TEVA traded up $0.28 during mid-day trading on Thursday, reaching $43.52. 9,218,408 shares of the stock traded hands, compared to its average volume of 6,859,138. The firm has a market cap of $50.72 billion, a price-to-earnings ratio of 101.22, a P/E/G ratio of 3.97 and a beta of 0.97. The stock has a fifty day simple moving average of $39.88 and a 200 day simple moving average of $34.96. Teva Pharmaceutical Industries Ltd. has a 12-month low of $24.01 and a 12-month high of $44.31. The company has a quick ratio of 0.74, a current ratio of 0.95 and a debt-to-equity ratio of 1.59.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Tuesday, November 3rd. The company reported $0.86 EPS for the quarter, beating analysts' consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The firm had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the prior year, the business posted $0.78 earnings per share. Teva Pharmaceutical Industries's revenue for the quarter was down 1.9% on a year-over-year basis. Sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently bought and sold shares of TEVA. First Trust Advisors LP lifted its holdings in Teva Pharmaceutical Industries by 693.7% in the 3rd quarter. First Trust Advisors LP now owns 84,589 shares of the company's stock valued at $3,350,000 after acquiring an additional 73,932 shares during the last quarter. Advisors Asset Management Inc. acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $1,175,000. Edmond DE Rothschild Holding S.A. acquired a new position in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $1,648,000. USS Investment Management Ltd bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $10,840,000. Finally, WealthTrust Axiom LLC bought a new stake in shares of Teva Pharmaceutical Industries in the 3rd quarter worth approximately $279,000. 54.05% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on TEVA. Leerink Partners boosted their price objective on shares of Teva Pharmaceutical Industries from $45.00 to $52.00 and gave the company an "outperform" rating in a research report on Thursday, November 5th. HC Wainwright began coverage on shares of Teva Pharmaceutical Industries in a research note on Monday, November 2nd. They set a "buy" rating and a $52.00 price objective on the stock. JPMorgan Chase & Co. raised their price objective on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Monday, October 12th. Zacks Research cut Teva Pharmaceutical Industries from a "hold" rating to a "strong sell" rating in a report on Tuesday, October 20th. Finally, Piper Sandler upped their target price on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an "overweight" rating in a research report on Thursday. Thirteen equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $48.15.

Teva Pharmaceutical Industries News Summary

Investors following TEVA have been watching these news items:

• Positive Sentiment: At its R&D Day, Teva set a goal of $6 billion to $7 billion in innovative-medicines revenue by 2030, saying revenue from these medicines has more than doubled since its 2023 growth strategy began. The company also highlighted pipeline candidates for Tourette syndrome, celiac disease and intestinal scarring—potential sources of future growth if developed successfully. Teva R&D Day announcement
• Neutral Sentiment: HC Wainwright made mixed earnings-estimate revisions: it raised its FY2027 EPS forecast to $3.07 from $3.03, but lowered estimates for some individual quarters, including Q4 2026 and Q3 2027. Its overall rating remains “Buy” with a $52 target. Teva analyst information
• Negative Sentiment: Healthcare shares were weaker in Wednesday afternoon trading, with the NYSE Healthcare Index down 0.6%, creating a possible sector-level headwind for TEVA. Healthcare sector update

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.